Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.4.2.28 extracted from

  • Lubin, M.; Lubin, A.
    Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy (2009), PLoS ONE, 4, e5735.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 2.4.2.28

Application

Application Comment Organism
drug development combination of 5'-methylthioadenosine with clinical cancer drugs 5-fluorouracil or 6-thioguanine, in the treatment of MTAP-negative tumors, may produce a significantly improved therapeutic index Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
ML-1 cell
-
 Homo sapiens
-
additional information A549 cells and MCF-7 cells are MTAP-negative cells Homo sapiens
-
skin fibroblast HF cell Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
5'-deoxyadenosine + phosphate
-
 Homo sapiens adenine + 5-deoxy-D-ribose 1-phosphate
-
 ?
5'-methylthioadenosine + phosphate
-
 Homo sapiens adenine + 5-methylthio-D-ribose 1-phosphate
-
 ?

Synonyms

Synonyms Comment Organism
methylthioadenosine phosphorylase
-
 Homo sapiens
MTAP
-
 Homo sapiens

General Information

General Information Comment Organism
physiological function MTAP substrates protect MTAP-positive cells from toxicity of adenine analogs 2,6-diaminopurine, 6-methylpurine, and 2-fluoroadenine and clinical cancer drugs 5-fluorouracil or 6-thioguanine. Adenine analog plus 5'-methylthioadenosine, kills MTAP-negative A549 lung tumor cells, while MTAP-positive human fibroblasts are protected, whereas in co-cultures of the breast tumor cell line, MCF-7, and HF cells, MCF-7 is inhibited or killed, while HF cells proliferate robustly Homo sapiens